Claus Henning Köhne

Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986

Claus Henning Köhne, Eric Van Cutsem, J. Wils et al. · Journal of Clinical Oncology · 2005 · 329 citations

Medicine, Oncology, Pharmacotherapy +16

Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to <i>KRAS</i> and <i>BRAF</i> mutation status.

Carsten Bokemeyer, Claus Henning Köhne, P. Rougier et al. · Journal of Clinical Oncology · 2010 · 82 citations

Medicine, Oncology, Pharmacotherapy +16

Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of <i>KRAS</i> and <i>BRAF</i> biomarker status with treatment outcome.

Eric Van Cutsem, István Láng, Gunnar Folprecht et al. · Journal of Clinical Oncology · 2010 · 62 citations

Medicine, Oncology, Pharmacology +17

An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients

Anne C. Regierer, R. Wolters, M.-P. Ufen et al. · Annals of Oncology · 2013 · 43 citations · Full text

Medicine, Biostatistics, Oncology +14

Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial

Claus Henning Köhne, D. Stroiakovski, Cr. Changchien et al. · Journal of Clinical Oncology · 2009 · 28 citations

Medicine, Oncology, Pharmacology +17